Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

semaglutide

- PMLiVE

PMEA 2015 win for Novo’s Changing Diabetes in Children

Company wins the EY Award for SociallyResponsible Initiatives

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

Evaluating the potential of a pre-launch prodct in a real-life setting

Using in-depth-interviews as well as a SmartPhone app to collect real patient cases from physicians to find out opportunity for a new product.

Research Partnership

Novo launches online news channel for haemophilia patients

New medical information website aims to be a 'simple, centralised repository'

- PMLiVE

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant

- PMLiVE

Keryx Biopharmaceuticals’ Fexeric approved in EU

New treatment option for chronic kidney disease

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

- PMLiVE

Novo collaborates with MIT on next-gen drug delivery devices

Aims to create new delivery vehicles for administration of peptides

- PMLiVE

Novo Nordisk acquires two US biopharma companies

Strikes deals with Calibrium LLC and MB2

- PMLiVE

Novo Nordisk plans $2bn expansion of its diabetes facilities

Comes as the Danish firm prepares to move oral semaglutideinto phase III trials

- PMLiVE

Novo Nordisk’s Victoza fails type 1 diabetes trial

Danish firm’s hopes dashed by latest data

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links